Momentum Bioscience is focused on developing rapid tests for bloodstream infection in patients suspected of sepsis.
SepsiSTAT® is our direct-from-blood, rapid screening technology, providing actionable results for suspected sepsis patients.
SepsiSTAT® contains our three proprietary capabilities:
- Sensitive and universal microbial capture
- Universal detection of viable microorganisms
- Organism profiling
Only by using Momentum’s proprietary universal pathogen capture, detection & identification capabilities can all patients suspected of sepsis expect actionable results for bloodstream infection in <3 hours. Not days.
This will have a significant impact on patient management, the management of antibiotics and help mitigate the problem of increasing antimicrobial resistance.
Momentum is seeking partners for joint commercialisation.
10 Fenlock Court,
Blenheim Office Park,
Tel: +44 (0)2921 677 910